The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Open accessAbstract
Background Elevated lipoprotein(a) (Lp[a]) is associated with aortic stenosis (AS). Oxidized phospholipids (OxPL) are key mediators of calcification in valvular cells and are carried by Lp(a).Objectives This study sought to determine whether Lp(a) and OxPL are associated with hemodynamic progression of AS and AS-related events.Methods OxPL on apolipoprotein B-100 (OxPL-apoB), which reflects the biological activity of Lp(a), and Lp(a) levels were measured in 220 patients with mild-to-moderate AS. The primary endpoint was the progression rate of AS, measured by the annualized increase in peak aortic jet velocity in m/s/year by Doppler echocardiography; the secondary endpoint was need for aortic valve replacement and cardiac death during 3.5 ± 1.2 years of follow-up.Results AS progression was faster in patients in the top tertiles of Lp(a) (peak aortic jet velocity: +0.26 ± 0.26 vs. +0.17 ± 0.21 m/s/year; p = 0.005) and OxPL-apoB (+0.26 ± 0.26 m/s/year vs. +0.17 ± 0.21 m/s/year; p = 0.01). After multivariable adjustment, elevated Lp(a) or OxPL-apoB levels remained independent predictors of faster AS progression. After adjustment for age, sex, and baseline AS severity, patients in the top tertile of Lp(a) or OxPL-apoB had increased risk of aortic valve replacement and cardiac death.Conclusions Elevated Lp(a) and OxPL-apoB levels are associated with faster AS progression and need for aortic valve replacement. These findings support the hypothesis that Lp(a) mediates AS progression through its associated OxPL and provide a rationale for randomized trials of Lp(a)-lowering and OxPL-apoB-lowering therapies in AS. (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin [ASTRONOMER]; NCT00800800).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical factors associated with faster stenosis progression include older age, female sex, severity of the stenosis and degree of aortic valve calcification at diagnosis, smoking, hypertension, obesity, metabolic syndrome, secondary hyperparathyroidism, renal failure elevated circulating levels of Lp(a), and increased activity of Lp-PLA2 (also called lipoprotein–associated phospholipase A2)51”
From Calcific aortic stenosis (2016) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the presence of elevated plasma Lp(a) (>50 mg per dL; the upper normal limit is <30 mg per dL)) is associated with a twofold faster stenosis progression51.”
From Calcific aortic stenosis (2016) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, Capoulade and colleagues showed that circulating Lp(a) and Ox-PL levels were independently associated with faster progression of calcific AS51.”
From Calcific aortic stenosis (2016) · cites this paper as [51]
In the citing paper
“prior studies have linked ApoB to the onset and accelerated progression of CAVD [38,39].”
From Identifying novel drug targets for calcific aortic valve disease through Mendelian randomization (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
Bonow, R. O., Carabello, B. A., Chatterjee, K., de Leon, A. C., Faxon, D. P., Freed, M. D., Gaasch, W. H., Lytle, B. W., Nishimura, R. A., O’Gara, P. T., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176857 · Cited by 8,487
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
Guidelines on the management of valvular heart disease
Vahanian, A. S., Baumgartner, H., Bax, J. J., Butchart, E., Dion, R., Filippatos, G. S., Flachskampf, F., Hall, R., Iung, B., Kasprzak, J. D., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl428 · Cited by 3,579
Guidelines on the management of valvular heart disease (version 2012)
Authors/Task Force Members, Vahanian, A., Alfieri, O., Andreotti, F., Antunes, M. J., Barón-Esquivias, G., Baumgartner, H., Borger, M. A., Carrel, T. P., De Bonis, M., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs109 · Cited by 3,559
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.536 · Cited by 3,523
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O’Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000029 · Cited by 2,566
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Guyton, R. A., O'Gara, P. T., Ruiz, C. E., Skubas, N. J., Sorajja, P., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.537 · Cited by 1,642
Genetic Associations with Valvular Calcification and Aortic Stenosis
Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1109034 · Cited by 1,008
Research works printed but not linked: 1
- Tsimikas, 2015, Antisense therapy targeting apolipoprotein (a) reduces plasma lipoprotein(a) Levels, Lancet
Cited by
Sorted by citations
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Self-citationA Test in Context: Lipoprotein(a)
Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.042 · Cited by 1,137
“This has been shown in clinical studies by measuring levels of OxPL on apoB-containing particles (OxPL-apoB), which primarily reflect the OxPL content of Lp(a) (10,11), which demonstrates that elevated OxPL-apoB levels are either similar or superior predictors to Lp(a) in the diagnosis or prognosis of CVD (13–18) and…”
BackgroundSelf-citationLindman, B. R., Clavel, M.-A., Mathieu, P., Iung, B., Lancellotti, P., Otto, C. M., & Pibarot, P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.6 · Cited by 982
Self-citationReyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Self-citationViney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationStructure, function, and genetics of lipoprotein (a)
Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067314 · Cited by 671
Nordestgaard, B. G., & Langsted, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r071233 · Cited by 575
Statin therapy increases lipoprotein(a) levels
Tsimikas, S., Gordts, P. L. S. M., Nora, C., Yeang, C., & Witztum, J. L. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz310 · Cited by 512
Self-citationWilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.04.010 · Cited by 522
Tsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes‐Soffer, G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.014 · Cited by 519
Self-citationZheng, K. H., Tsimikas, S., Pawade, T., Kroon, J., Jenkins, W. S. A., Doris, M. K., White, A. C., Timmers, N. K. L. M., Hjortnaes, J., Rogers, M. A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.070 · Cited by 353
Self-citationAn update on lipid oxidation and inflammation in cardiovascular diseases
Zhong, S., Li, L., Shen, X., Li, Q., Xu, W., Wang, X., Tao, Y., & Yin, H. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.03.036 · Cited by 342
European Society of Cardiology: the 2023 Atlas of Cardiovascular Disease Statistics
Timmis, A., Aboyans, V., Vardas, P. E., Townsend, N. P., Torbica, A., Kavousi, M., Boriani, G., Huculeci, R., Kazakiewicz, D., Scherr, D., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae466 · Cited by 371
Nissen, S. E., Wolski, K., Balog, C., Swerdlow, D. I., Scrimgeour, A., Rambaran, C., Wilson, R. J., Boyce, M., Ray, K. K., Cho, L., et al. (2022) · JAMA · doi:10.1001/jama.2022.5050 · Cited by 308
Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease
Boffa, M. B., & Koschinsky, M. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0153-2 · Cited by 298
Elevated Lipoprotein(a) and Risk of Ischemic Stroke
Langsted, A., Nordestgaard, B. G., & Kamstrup, P. R. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.524 · Cited by 272
Lipoprotein(a) and Cardiovascular Disease
Kamstrup, P. R. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa247 · Cited by 266
HEART UK consensus statement on Lipoprotein(a): A call to action
Cegla, J., Neely, R. D. G., France, M. W., Ferns, G. A., Byrne, C. D., Halcox, J., Datta, D. B. N., Capps, N. E., Shoulders, C. C., Qureshi, N., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.10.011 · Cited by 248
Strianese, O., Rizzo, F. M., Ciccarelli, M., Galasso, G., D’Agostino, Y., Salvati, A., Giudice, C. D., Tesorio, P., & Rusciano, M. R. (2020) · Genes · doi:10.3390/genes11070747 · Cited by 269
Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases
Kronenberg, F. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6648-3 · Cited by 233
Varvel, S. A., McConnell, J. P., & Tsimikas, S. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308011 · Cited by 224
Self-citationGencer, B., Kronenberg, F., Stroes, E. S. G., & Mach, F. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx033 · Cited by 189
Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis
de Boer, L. M., Oorthuys, A. O. J., Wiegman, A., Langendam, M. W., Kroon, J., Spijker, R., Zwinderman, A. H., & Hutten, B. A. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab171 · Cited by 189
Medical Treatment of Aortic Stenosis
Marquis‐Gravel, G., Redfors, B., Leon, M. B., & Généreux, P. (2016) · Circulation · doi:10.1161/circulationaha.116.023997 · Cited by 181
Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)
Tsimikas, S., Moriarty, P. M., & Stroes, E. S. G. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.051 · Cited by 155
Self-citationOxidized phospholipids in cardiovascular disease
Tsimikas, S., & Witztum, J. L. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00937-4 · Cited by 166
Self-citationLPA Gene, Ethnicity, and Cardiovascular Events
Lee, S. R., Prasad, A., Choi, Y. S., Xing, C., Clopton, P., Witztum, J. L., & Tsimikas, S. (2016) · Circulation · doi:10.1161/circulationaha.116.024611 · Cited by 141
Self-citationContext-Dependent Role of Oxidized Lipids and Lipoproteins in Inflammation
Miller, Y. I., & Shyy, J. Y.-J. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.11.002 · Cited by 141
Oxidized phospholipids in Doxorubicin-induced cardiotoxicity
Koleini, N., Nickel, B. E., Edel, A. L., Fandrich, R. R., Ravandi, A., & Kardami, E. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.01.032 · Cited by 138
Bergmark, B. A., O’Donoghue, M. L., Murphy, S. A., Kuder, J. F., Ezhov, M. V., Ceška, R., Gouni-Berthold, I., Jensen, H. K., Tokgozoglu, S. L., Mach, F., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0728 · Cited by 137
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
Graham, M. J., Viney, N., Crooke, R. M., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r052258 · Cited by 133
Self-citationLipoprotein(a) and its role in inflammation, atherosclerosis and malignancies
Orsó, E., & Schmitz, G. (2017) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-017-0084-1 · Cited by 125
Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease
Cho, K. I., Sakuma, I., Sohn, I. S., Jo, S., & Koh, K. K. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.029 · Cited by 126
Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective
Arsenault, B. J., & Kamstrup, P. R. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.015 · Cited by 123
Self-citationEnas, E. A., Varkey, B., Dharmarajan, T. S., Paré, G., & Bahl, V. K. (2019) · Indian Heart Journal · doi:10.1016/j.ihj.2019.03.004 · Cited by 128
Perrot, N., Verbeek, R., Sandhu, M. S., Boekholdt, S. M., Hovingh, G. K., Wareham, N. J., Khaw, K., & Arsenault, B. J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.11.010 · Cited by 120
Self-citationLu, Y., Cui, X., Zhang, L., Wang, X., Xu, Y., Qin, Z., Liu, G., Wang, Q., Tian, K., Lim, K. S., et al. (2022) · Aging and Disease · doi:10.14336/ad.2021.0929 · Cited by 117
Qingchun, Z., Song, R., Fullerton, D. A., Ao, L., Zhai, Y., Li, S., Ballak, D. B., Cleveland, J. C., Reece, T. B., McKinsey, T. A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619667114 · Cited by 115
Yeang, C., Hung, M., Byun, Y. S., Clopton, P., Yang, X., Witztum, J. L., & Tsimikas, S. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.01.005 · Cited by 110
Self-citationEvaluating Medical Therapy for Calcific Aortic Stenosis
Lindman, B. R., Sukul, D., Dweck, M. R., Madhavan, M. V., Arsenault, B. J., Coylewright, M. J., Merryman, W. D., Newby, D. E., Lewis, J., Harrell, F. E., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.09.1367 · Cited by 115
Self-citationRole of oxidative stress in calcific aortic valve disease and its therapeutic implications
Greenberg, H. Z. E., Zhao, G., Shah, A. M., & Zhang, M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab142 · Cited by 115
Vinci, P., Girolamo, F. G. D., Panizon, E., Tosoni, L. M., Cerrato, C., Pellicori, F., Altamura, N., Pirulli, A., Zaccari, M., Biasinutto, C., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20186721 · Cited by 119
Capoulade, R., Yeang, C., Chan, K. L., Pîbarot, P., & Tsimikas, S. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.3798 · Cited by 107
Self-citationYang, X., Lee, S.-R., Choi, Y.-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witztum, J. L., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066399 · Cited by 103
Self-citationLipoprotein(a) is associated with the onset but not the progression of aortic valve calcification
Kaiser, Y., van der Toorn, J. E., Singh, S. S., Zheng, K. H., Kavousi, M., Sijbrands, E. J. G., Stroes, E. S. G., Vernooij, M. W., de Rijke, Y. B., Boekholdt, S. M., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac377 · Cited by 98
Current therapies for lowering lipoprotein (a)
van Capelleveen, J. C., van der Valk, F. M., & Stroes, E. S. G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r053066 · Cited by 97
Lipoprotein(a) Induces Human Aortic Valve Interstitial Cell Calcification
Yu, B., Hafiane, A., Thanassoulis, G., Ott, L. C., Filwood, N., Cerruti, M., Gourgas, O., Shum‐Tim, D., Kindi, H. N. A., de Varennes, B., et al. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.03.015 · Cited by 100
Nsaibia, M. J., Boulanger, M., Bouchareb, R., Mkannez, G., Quang, K. L., Hadji, F., Argaud, D., Dahou, A., Bossé, Y., Koschinsky, M. L., et al. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx089 · Cited by 98
Self-citationDevelopment of calcific aortic valve disease: Do we know enough for new clinical trials?
Kostyunin, A. E., Yuzhalin, A. E., Ovcharenko, E. A., & Kutikhin, A. G. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.05.016 · Cited by 102
Thanassoulis, G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r051870 · Cited by 94
Pathophysiology of Aortic Stenosis and Future Perspectives for Medical Therapy
Zheng, K. H., Tzolos, E., & Dweck, M. R. (2019) · Cardiology Clinics · doi:10.1016/j.ccl.2019.09.010 · Cited by 106
Diet and Lp(a): Does Dietary Change Modify Residual Cardiovascular Risk Conferred by Lp(a)?
Enkhmaa, B., Petersen, K. H., Kris‐Etherton, P. M., & Berglund, L. (2020) · Nutrients · doi:10.3390/nu12072024 · Cited by 98
Lipoprotein(a) and Cardiovascular Disease in Chinese Population
Li, J., Ma, C.-S., Zhao, D. H., Yan, X.-W., Li, J., Ma, C., Zhao, D. H., Yan, X.-W., Ye, P., Chen, H., et al. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.08.015 · Cited by 96
Adaptive immune cells in calcific aortic valve disease
Raddatz, M. A., Madhur, M. S., & Merryman, W. D. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00100.2019 · Cited by 97
Nsaibia, M. J., Mahmut, A., Boulanger, M., Arsenault, B. J., Bouchareb, R., Simard, S., Witztum, J. L., Clavel, M.-A. A., Pîbarot, P., Bossé, Y., et al. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12519 · Cited by 92
Self-citationBiomarkers of Calcific Aortic Valve Disease
Small, A., Kiss, D., Giri, J. S., Anwaruddin, S., Siddiqi, H. K., Guerraty, M. A., Chirinos, J. A., Ferrari, G. M., & Rader, D. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308615 · Cited by 98
Lipoprotein(a) and Cardiovascular Diseases ― Revisited ―
Jang, A. Y., Han, S. H., Sohn, I. S., Oh, P. C., & Koh, K. K. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0051 · Cited by 97
Moriarty, P. M., Varvel, S. A., Gordts, P. L. S. M., McConnell, J. P., & Tsimikas, S. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.308704 · Cited by 89
Self-citationLipoprotein apheresis for lipoprotein(a) and cardiovascular disease
Moriarty, P. M., Gray, J. V., & Gorby, L. K. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.09.010 · Cited by 89
Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology
Koschinsky, M. L., & Boffa, M. B. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.001 · Cited by 94
Lipoprotein(a): A missing culprit in the management of athero‐thrombosis?
Ferretti, G., Bacchetti, T., Johnston, T. P., Banach, M., Pirro, M., & Sahebkar, A. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26050 · Cited by 92
Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis
Yeang, C., Wilkinson, M. J., & Tsimikas, S. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000300 · Cited by 89
Self-citationRNA Therapeutics in Cardiovascular Precision Medicine
Laina, A., Gatsiou, A., Georgiopoulos, G. A., Stamatelopoulos, K. S., & Stellos, K. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00953 · Cited by 90
Lipoprotein(a) and inflammation: A dangerous duet leading to endothelial loss of integrity
Pirro, M., Bianconi, V., Paciullo, F., Mannarino, M. R., Bagaglia, F., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.001 · Cited by 87
Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313864 · Cited by 89
Self-citationTorzewski, M., Ravandi, A., Yeang, C., Edel, A. L., Bhindi, R., Kath, S., Twardowski, L., Schmid, J. O., Yang, X., Franke, U. F. W., et al. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.02.004 · Cited by 87
Self-citationSex-Specific Features of Calcific Aortic Valve Disease
Summerhill, V. I., Moschetta, D., Orekhov, A. N., Poggio, P., & Myasoedova, V. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165620 · Cited by 85
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.007 · Cited by 89
Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease
Kamstrup, P. R., Hung, M., Witztum, J. L., Tsimikas, S., & Nordestgaard, B. G. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308761 · Cited by 85
Self-citationThe effect of statins on valve function and calcification in aortic stenosis: a meta-analysis
Zhao, Y., Nicoll, R., He, Y. H., & Henein, M. Y. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.023 · Cited by 80
Lu, J., Chen, B., Chen, T., Guo, S., Xue, X., Chen, Q., Zhao, M., Xia, L., Zhu, Z., Zheng, L., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.04.032 · Cited by 84
Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis
Arsenault, B. J., Loganath, K., Girard, A., Botezatu, S., Zheng, K. H., Tzolos, E., Abdoun, K., Tastet, L., Capoulade, R., Côté, N., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.1882 · Cited by 80
Self-citationSerbulea, V., Upchurch, C. M., Ahern, K. W., Bories, G. F. P., Voigt, P. E., DeWeese, D. E., Meher, A. K., Harris, T. E., & Leitinger, N. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.11.002 · Cited by 74
Rodrigo Alonso, K., Mata, P., Muñiz-Grijalvo, O., Fuentes, F. J., Díaz, J. L., Zambón, D., Tomás, M., Martı́n, C., Moyon, T., Croyal, M., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.038 · Cited by 74
Lee, S. H., Kim, N., Kim, M., Woo, S.-H., Han, I., Park, J., Kim, K., Park, K. S., Kim, K., Shim, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33202-2 · Cited by 70
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 71
Aortic stenosis and diabetes mellitus: An ominous combination
Banovic, M. D., Athithan, L., & McCann, G. P. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118820657 · Cited by 70
Bhatia, H. S., & Wilkinson, M. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206040 · Cited by 67
Association of LPA Variants With Aortic Stenosis
Chen, H. Y., Dufresne, L., Burr, H., Ambikkumar, A., Yasui, N., Luk, K., Ranatunga, D. K., Whitmer, R. A., Lathrop, M. G., Engert, J. C., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4266 · Cited by 64
Genetics and Pathophysiological Mechanisms of Lipoprotein(a)‐Associated Cardiovascular Risk
Volgman, A. S., Koschinsky, M. L., Mehta, A., & Rosenson, R. S. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033654 · Cited by 68
Tsimikas, S. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000237 · Cited by 64
Self-citationNovel pharmacological targets for calcific aortic valve disease: Prevention and treatments
Myasoedova, V. A., Ravani, A. L., Frigerio, B., Valerio, V., Moschetta, D., Songia, P., & Poggio, P. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.020 · Cited by 62
Arsenault, B. J., Petrides, F., Tabet, F., Bao, W., Hovingh, G. K., Boekholdt, S. M., Ramin‐Mangata, S., Meilhac, O., DeMicco, D. A., Rye, K., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.10.001 · Cited by 60
Self-citationDesprés, A.-A., Perrot, N., Poulin, A., Tastet, L. L., Shen, M., Chen, H. Y., Bourgeois, R., Trottier, M., Tessier, M., Guimond, J. V., et al. (2019) · CJC Open · doi:10.1016/j.cjco.2019.03.004 · Cited by 60
Self-citationSwerdlow, D. I., Rider, D. A., Yavari, A., Lindholm, M., Campion, G., & Nissen, S. E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab100 · Cited by 58
What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
Cybulska, B., Kłosiewicz−Latoszek, L., Penson, P. E., & Banach, M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.04.004 · Cited by 59
Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations
Shah, N. P., Pajidipati, N. J., McGarrah, R. W., Návar, A. M., Vemulapalli, S., Blazing, M. A., Shah, S. H., Hernandez, A. F., & Patel, M. R. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.03.043 · Cited by 58
Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease
Tada, H., Takamura, M., & Kawashiri, M. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17034 · Cited by 56
Pantelidis, P., Oikonomou, E. K., Lampsas, S., Zakynthinos, G. Ε., Lysandrou, A., Kalogeras, K. I., Katsianos, E., Theofilis, P., Siasos, G., Vavuranakis, M., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad062 · Cited by 56
Broeders, W., Bekkering, S., Messaoudi, S. E., Joosten, L. A. B., van Royen, N., & Riksen, N. P. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00935-6 · Cited by 57
Perrot, N., Thériault, S., Christian Dina, C., Chen, H. Y., Boekholdt, S. M., Rigade, S., Després, A.-A., Poulin, A., Capoulade, R., Tourneau, T. L., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1581 · Cited by 56
Self-citationAlexandros, D. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160009 · Cited by 52
Porras, A. M., Westlund, J. A., Evans, A. D., & Masters, K. S. B. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704637115 · Cited by 52
Lipoprotein(a) and calcific aortic valve stenosis: A systematic review
Guddeti, R. R., Patil, S., Ahmed, A., Sharma, A., Aboeata, A., Lavie, C. J., & Alla, V. M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.06.002 · Cited by 52
Lipoprotein(a) Levels at Birth and in Early Childhood: The COMPARE Study
Strandkjær, N., Hansen, M. K., Nielsen, S. T., Frikke‐Schmidt, R., Tybjærg‐Hansen, A., Nordestgaard, B. G., Tabor, A., Bundgaard, H., Iversen, K. K., & Kamstrup, P. R. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab734 · Cited by 51
de Isla, L. P., Watts, G. F., Rodrigo Alonso, K., Díaz-Díaz, J. L., Muñiz-Grijalvo, O., Zambón, D., Fuentes, F. J., de Andrés, R., Padró, T., López‐Miranda, J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1066 · Cited by 51
ApoC-III is a novel inducer of calcification in human aortic valves
Schlotter, F., de Freitas, R. C. C., Rogers, M. A., Blaser, M. C., Wu, P.-J., Higashi, H., Halu, A., Iqbal, F., Andraski, A. B., Rodia, C. N., et al. (2021) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015700 · Cited by 49
Zhou, T., Wang, Y., Liu, M., Huang, Y., Shi, J., Dong, N., & Xu, K. (2020) · Phytotherapy Research · doi:10.1002/ptr.6674 · Cited by 49
Bonetti, A., Marchini, M., & Ortolani, F. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.78 · Cited by 47
Effect of bicuspid aortic valve phenotype on progression of aortic stenosis
Shen, M., Tastet, L. L., Capoulade, R., Arsenault, M., Bédard, É., Clavel, M.-A. A., & Pîbarot, P. (2020) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaa068 · Cited by 51
Self-citation
Metadata
- Authors
- Capoulade, R., Chan, K. L., Yeang, C., Mathieu, P., Bossé, Y., Dumesnil, J. G., Tam, J. W., Teo, K. K., Mahmut, A., Yang, X., Witztum, J. L., Arsenault, B. J., Després, J.-P., Pibarot, P., & Tsimikas, S.
- Affiliations
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Ottawa Heart Institute (CA)
- University of California San Diego (US)
- St. Boniface Hospital (CA)
- McMaster University (CA)
- Corresponding author
- Tsimikas, Sotirios
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 66
- Issue
- 11
- Pages
- 1236-1246
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W1609565130
- Cited by
- 417
- References
- 45
- Citations by year
- 2026: 26 · 2025: 49 · 2024: 37 · 2023: 37 · 2022: 52 · 2021: 30 · 2020: 40 · 2019: 47 · 2018: 26 · 2017: 38 · 2016: 32 · 2015: 3
- FWCI
- 24.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Corpus Université Laval (Université Laval) (submittedVersion)
- Funders
- Abbott Laboratories
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- National Institutes of Health (HL055798, HL088093)
- University of California, San Diego
- Pfizer Canada
- Eli Lilly Canada
- Canadian Institutes of Health Research (MOP# 114997, MOP-245048, 114997, 245048)
- National Heart, Lung, and Blood Institute (HL-055798, HL093767, R01HL093767, HL119828, P01HL055798, R01HL119828, HL-088093, P01HL088093)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- aortic stenosis, calcific aortic stenosis, lipoprotein(a), oxidized phospholipids, apolipoprotein B-100, disease progression, aortic jet velocity, aortic valve replacement, cardiovascular mortality, valve calcification, Lp(a)-lowering therapy
- MeSH terms
- Adult, Aged, Aortic Valve, Aortic Valve Stenosis, Calcinosis, Death, Female, Humans, Male, Middle Aged, Oxidation-Reduction, Phospholipids, Ultrasonography, Biomarkers, Lipoprotein(a), Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
